Fish Consumption Linked With Better Survival Outcomes in Colon Cancer

Video

This video examines the results of a prospective study that looked at associations between survival outcomes and fish and omega-3 fatty acid intake among colon cancer patients.

In this video, Erin Van Blarigan, ScD, of the University of California, San Francisco, discusses the results of a prospective study that looked at associations between survival outcomes and fish and long-chain omega-3 fatty acid intake after a colon cancer diagnosis.

The study included 1,011 stage III colon cancer patients who were part of an adjuvant chemotherapy trial, and found that patients who consumed dark meat fish at least twice per month had longer recurrence-free survival (hazard ratio [HR], 0.61; 0.44–0.83; P = .005), disease-free survival (HR, 0.64; 0.48–0.86; P = .007), and overall survival (HR, 0.68; 0.48–0.97; P = .05) compared with those who consumed no fish. The study also found that in patients with COX2 tumor expression, long-chain omega-3 fatty acid was associated with improved disease-free survival.

Results of the study (abstract 585) were presented last month at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.

Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Related Content